{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+-+50+mg&page=2", "query": { "intervention": "Placebo - 50 mg", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+-+50+mg&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-29T09:30:08.314Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00799617", "title": "The Testosterone Trials in Older Men", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Andropause" ], "interventions": [ { "name": "AndroGel® (testosterone gel)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Pennsylvania", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "65 Years", "maximum_age": null, "sex": "MALE", "summary": "65 Years and older · Male only" }, "enrollment_count": 790, "start_date": "2009-11", "completion_date": "2018-12", "has_results": true, "last_update_posted_date": "2019-02-21", "last_synced_at": "2026-09-29T09:30:08.314Z", "location_count": 12, "location_summary": "Birmingham, Alabama • La Jolla, California • Torrance, California + 9 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "La Jolla", "state": "California" }, { "city": "Torrance", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Gainesville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00799617" }, { "nct_id": "NCT00949884", "title": "Olmesartan Comparison to Losartan in Hypertensive Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Hypertension" ], "interventions": [ { "name": "olmesartan medoxomil", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "losartan potassium", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Daiichi Sankyo", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 941, "start_date": "2009-08", "completion_date": "2010-01", "has_results": true, "last_update_posted_date": "2011-03-09", "last_synced_at": "2026-09-29T09:30:08.314Z", "location_count": 20, "location_summary": "Mesa, Arizona • Phoenix, Arizona • Harbor City, California + 17 more", "locations": [ { "city": "Mesa", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Harbor City", "state": "California" }, { "city": "Tustin", "state": "California" }, { "city": "Westlake Village", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00949884" }, { "nct_id": "NCT01500226", "title": "Ph 3 Safety/Efficacy Study of Rolapitant for Prevention of CINV in Subjects Receiving Moderately Emetogenic Chemotherapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chemotherapy-induced Nausea and Vomiting" ], "interventions": [ { "name": "Rolapitant", "type": "DRUG" }, { "name": "Granisetron", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Tesaro, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1369, "start_date": "2012-02", "completion_date": "2014-02", "has_results": true, "last_update_posted_date": "2016-03-02", "last_synced_at": "2026-09-29T09:30:08.314Z", "location_count": 1, "location_summary": "Waltham, Massachusetts", "locations": [ { "city": "Waltham", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01500226" }, { "nct_id": "NCT01058083", "title": "Safety Study of BMS-770767 in Subjects With Hypercholesterolemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Dyslipidemia" ], "interventions": [ { "name": "BMS-770767", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 81, "start_date": "2010-05", "completion_date": "2011-03", "has_results": false, "last_update_posted_date": "2012-04-19", "last_synced_at": "2026-09-29T09:30:08.314Z", "location_count": 2, "location_summary": "Little Rock, Arkansas • San Antonio, Texas", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01058083" }, { "nct_id": "NCT01854294", "title": "GM604 Phase 2A Randomized Double-blind Placebo Controlled Pilot Trial in Amyotrophic Lateral Disease (ALS)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Amyotrophic Lateral Sclerosis" ], "interventions": [ { "name": "GM604", "type": "DRUG" }, { "name": "Placebo comparator", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genervon Biopharmaceuticals, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2013-08", "completion_date": "2014-07", "has_results": false, "last_update_posted_date": "2021-04-27", "last_synced_at": "2026-09-29T09:30:08.314Z", "location_count": 2, "location_summary": "Boston, Massachusetts • New York, New York", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01854294" }, { "nct_id": "NCT00754494", "title": "Erlotinib Hydrochloride in Treating Patients With Stage I-III Colorectal Cancer or Adenoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Adenomatous Polyp", "Recurrent Colon Cancer", "Recurrent Rectal Cancer", "Stage I Colon Cancer", "Stage I Rectal Cancer", "Stage IIA Colon Cancer", "Stage IIA Rectal Cancer", "Stage IIB Colon Cancer", "Stage IIB Rectal Cancer", "Stage IIC Colon Cancer", "Stage IIC Rectal Cancer", "Stage IIIA Colon Cancer", "Stage IIIA Rectal Cancer", "Stage IIIB Colon Cancer", "Stage IIIB Rectal Cancer", "Stage IIIC Colon Cancer", "Stage IIIC Rectal Cancer" ], "interventions": [ { "name": "erlotinib hydrochloride", "type": "DRUG" }, { "name": "placebo", "type": "OTHER" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 45, "start_date": "2008-07", "completion_date": "2013-09", "has_results": true, "last_update_posted_date": "2015-01-06", "last_synced_at": "2026-09-29T09:30:08.314Z", "location_count": 3, "location_summary": "Long Beach, California • Orange, California • Chicago, Illinois", "locations": [ { "city": "Long Beach", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00754494" }, { "nct_id": "NCT01179737", "title": "Efficacy, Safety, Tolerability and Pharmacokinetics (PK) of Nilotinib (AMN107) in Pulmonary Arterial Hypertension (PAH)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pulmonary Arterial Hypertension" ], "interventions": [ { "name": "Nilotinib", "type": "DRUG" }, { "name": "Placebo to nilotinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 23, "start_date": "2010-07", "completion_date": "2013-01", "has_results": true, "last_update_posted_date": "2014-05-01", "last_synced_at": "2026-09-29T09:30:08.314Z", "location_count": 5, "location_summary": "Boston, Massachusetts • Ann Arbor, Michigan • Chapel Hill, North Carolina + 2 more", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Chapel Hill", "state": "North Carolina" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT01179737" }, { "nct_id": "NCT01178281", "title": "Study of Pomalidomide in Persons With Myeloproliferative-Neoplasm-Associated Myelofibrosis and RBC-Transfusion-Dependence", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Primary Myelofibrosis", "MPN-associated Myelofibrosis" ], "interventions": [ { "name": "Pomalidomide 0.5 mg", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Pomalidomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 267, "start_date": "2010-09-08", "completion_date": "2018-05-15", "has_results": true, "last_update_posted_date": "2019-07-17", "last_synced_at": "2026-09-29T09:30:08.314Z", "location_count": 17, "location_summary": "Scottsdale, Arizona • Los Angeles, California • Gainesville, Florida + 12 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT01178281" }, { "nct_id": "NCT02794519", "title": "A Phase 2a Study to Evaluate the Effects of Sirukumab in Subjects With Severe Poorly Controlled Asthma", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Asthma" ], "interventions": [ { "name": "Sirukumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Rescue medication", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 0, "start_date": "2016-09-23", "completion_date": "2016-10-04", "has_results": false, "last_update_posted_date": "2018-08-31", "last_synced_at": "2026-09-29T09:30:08.314Z", "location_count": 5, "location_summary": "Long Beach, California • Aventura, Florida • Cincinnati, Ohio + 1 more", "locations": [ { "city": "Long Beach", "state": "California" }, { "city": "Aventura", "state": "Florida" }, { "city": "Cincinnati", "state": "Ohio" }, { "city": "Richmond", "state": "Virginia" }, { "city": "Richmond", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02794519" }, { "nct_id": "NCT01456195", "title": "Comparison of TAK-875 (Fasiglifam) With Placebo in Participants With Type 2 Diabetes", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "Fasiglifam", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Takeda", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 421, "start_date": "2011-11", "completion_date": "2013-07", "has_results": true, "last_update_posted_date": "2016-04-05", "last_synced_at": "2026-09-29T09:30:08.314Z", "location_count": 55, "location_summary": "Dothan, Alabama • Muscle Shoals, Alabama • Goodyear, Arizona + 52 more", "locations": [ { "city": "Dothan", "state": "Alabama" }, { "city": "Muscle Shoals", "state": "Alabama" }, { "city": "Goodyear", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Long Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01456195" } ] }